Variable | n | OR (95%CI) | P-value |
---|---|---|---|
Population | |||
Trial patients | 292 | Reference | |
Real-world patients | 141 | 1.13 (0.88-1.44) | 0.34 |
Age (years) | |||
< 70 | 349 | Reference | |
≥ 70 | 84 | 1.25 (0.94-1.66) | 0.118 |
Gender | |||
Male | 225 | Reference | |
Female | 208 | 0.92 (0.73-1.15) | 0.454 |
Stage | |||
IV | 413 | Reference | |
IIIB | 20 | 0.85 (0.48-1.22) | 0.584 |
ECOG PS | |||
0 | 128 | Reference | |
1 | 298 | 1.95 (1.48-2.55) | < 0.001 |
2 | 7 | 3.82 (1.75-8.33) | 0.001 |
Presence of brain metastases | |||
No | 374 | Reference | |
Yes | 59 | 1.35 (0.99-1.85) | 0.059 |
Histology tumor | |||
Adenocarcinoma | 400 | Reference | |
Large cell carcinoma | 15 | 1.24 (0.68-2.26) | 0.488 |
Adenosquamous | 3 | 0.94 (0.23-3.79) | 0.932 |
Other | 11 | 0.59 (0.24-1.43) | 0.246 |
Not otherwise specified (NOS) | 3 | 2.45 (0.78-7.65) | 0.123 |
PD-L1 expression | |||
< 1% | 141 | Reference | |
1-49% | 86 | 0.92 (0.66-1.28) | 0.606 |
> 50% | 76 | 0.53 (0.36-0.77) | 0.001 |
Unknown | 130 | 1.24 (0.94-1.63) | 0.13 |